IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.
About IPO Scanner
IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.
Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.
Details of client bank account
For any query / feedback / clarifications, email at
[email protected].
Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.
© 2026 IPO Scanner. All rights reserved.
Want to stay updated?Subscribe to our newsletter

Issue Size
$20.02M
Price Range
$6.00 - $8.00
Shares
13.1M o/s · 2.86M offered
Sector
Healthcare
Filed
Jul 17, 2026
NuvOx Therapeutics, Inc.
NuvOx Therapeutics is a clinical-stage biopharmaceutical company developing innovative oxygen therapeutic solutions for the treatment of diseases where hypoxia, or lack of oxygen, plays a critical role. Our product candidate is NanO2, the API of which is dodecafluoropentane.
NanO2 is administered intravenously as an emulsified liquid, containing nano-sized droplets that after entering the body, due to the human body temperature, convert to a gas, which enables them to deliver more oxygen than when in the liquid state.
The focus of our clinical research and development to date has been on the administration of NanO2 to treat acute ischemic stroke, GBM, ARDS, and sickle cell anemia.
Ticker, listing venue and issuer profile
Pricing terms and IPO milestones
Key valuation ratios and metrics
Historical financial performance
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| S-1 | Jul 17, 2026 | General form for registration of securities under the Securities Act of 1933 |
| DRS/A | May 6, 2025 | [Amend] [Cover] Draft Registration Statement |
| DRS/A | Apr 8, 2025 | [Amend] [Cover] Draft Registration Statement |
| DRS | Dec 23, 2024 | [Cover] Draft Registration Statement |
| D | Nov 22, 2024 | Notice of Exempt Offering of Securities |
| D | Feb 15, 2023 | Notice of Exempt Offering of Securities |
Contact and headquarters details
Key executives and officers
Evan Unger, M.D.
Executive Chairman of the Board
Rong Wang
President, Chief Executive Officer and Director
Shien McCullough, CPA
Interim Chief Financial Officer
Jennifer L. H. Johnson, Ph.D.
Chief Operating Officer
Richard Carmona, M.D.
Director
Jon S. Saxe
Director
Jonathan T. Schilling
Director
Marvin J. Slepian, M.D
Director
Wilson W. Cheung, CPA
Director